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Abstract 
Background: To compare illness characteristics, treatment history, response and durability, and suicidality scores 
over a 5‑year period in patients with treatment‑resistant bipolar depression participating in a prospective, multicenter, 
open‑label registry and receiving Vagus Nerve Stimulation Therapy (VNS Therapy) plus treatment‑as‑usual (VNS + TAU) 
or TAU alone.
Methods: Response was defined as ≥ 50% decrease from baseline Montgomery–Åsberg Depression Rating Scale 
(MADRS) total score at 3, 6, 9, or 12 months post‑baseline. Response was retained while MADRS score remained ≥ 40% 
lower than baseline. Time‑to‑events was estimated using Kaplan–Meier (KM) analysis and compared using log‑rank 
test. Suicidality was assessed using the MADRS Item 10 score.
Results: At baseline (entry into registry), the VNS + TAU group (N = 97) had more episodes of depression, psychiatric 
hospitalizations, lifetime suicide attempts and higher suicidality score, more severe symptoms (based on MADRS and 
other scales), and higher rate of prior electroconvulsive therapy than TAU group (N = 59). Lifetime use of medications 
was similar between the groups (a mean of 9) and was consistent with the severe treatment‑resistant nature of their 
depression. Over 5 years, 63% (61/97) in VNS + TAU had an initial response compared with 39% (23/59) in TAU. The 
time‑to‑initial response was significantly quicker for VNS + TAU than for TAU (p < 0.03). Among responders in the first 
year after implant, the KM estimate of the median time‑to‑relapse from initial response was 15.2 vs 7.6 months for 
VNS + TAU compared with TAU (difference was not statistically significant). The mean reduction in suicidality score 
across the study visits was significantly greater in the VNS + TAU than in the TAU group (p < 0.001).
Conclusions: The patients who received VNS + TAU included in this analysis had severe bipolar depression that had 
proved extremely difficult to treat. The TAU comparator group were similar though had slightly less severe illnesses 
on some measures and had less history of suicide attempts. Treatment with VNS + TAU was associated with a higher 
likelihood of attaining a response compared to TAU alone. VNS + TAU was also associated with a significantly greater 
mean reduction in suicidality.
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is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
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Background
Patients with bipolar disorder are symptomatic about 
50% of the time, the vast majority of which is depres-
sion (Judd et al. 2002, 2003). However, treatment options 
for bipolar depression are limited. For example, the UK 
National Institute for Health and Social Care (NICE) 
guidelines for the management of bipolar depression list 
just 3 treatments that are supported by replicated rand-
omized controlled trials: lamotrigine, quetiapine, and 
olanzapine (with or without fluoxetine) (National Insti-
tute for Health and Care Excellence 2014). Since publi-
cation of the NICE guidelines, additional evidence has 
emerged from randomized controlled trials supporting 
the efficacy of lurasidone for the acute treatment of bipo-
lar depression (Loebel et al. 2014a, b). This limited num-
ber of treatment options for bipolar depression is further 
compromised as quetiapine and olanzapine are often 
poorly tolerated due to weight gain and sedation (Cala-
brese et al. 2005; Tohen et al. 2003).
The clinical challenge of managing bipolar depression 
is further illustrated by observations of high rates of anti-
depressant usage (Kessing et  al. 2016; Yoon et  al. 2018) 
despite evidence of questionable efficacy (National Insti-
tute for Health and Care Excellence 2014; Sidor and Mac-
queen 2011). The implication is that many patients suffer 
from treatment-resistant bipolar depression (TRBD). The 
prevalence of TRBD is unknown due to a lack of a con-
sensus definition (Hidalgo-Mazzei et al. 2019). However, 
it is known that about 50% and 30% of depressed bipolar 
patients remain depressed at 6 and 12  months, respec-
tively, following initiation of antidepressant treatment; 
and the lack of treatment effects is due to non-response, 
intolerance, or non-acceptance of treatment (Kupfer et al. 
2000). As a result, TRBD is the major contributor to the 
enormous burden of disease associated with bipolar dis-
order (Ferrari et al. 2016).
Given the significant unmet need with regards to the 
management of bipolar depression, it is important that 
alternative treatment options for patients with TRBD are 
explored. One potential option is Vagus Nerve Stimula-
tion Therapy (VNS Therapy).
VNS Therapy has primarily been examined in unipo-
lar treatment-resistant depression (TRD). The largest 
data set supporting its use in TRD is a 5-year VNS TRD 
registry of nearly 500  participants (representing both 
unipolar and bipolar TRD) who received adjunctive 
VNS Therapy plus treatment-as-usual (VNS + TAU). 
In this registry, the VNS-implanted TRD participants 
were compared with 300  other TRD participants with 
similar clinical presentations who received only TAU 
(Aaronson et al. 2017). It is important to note that the 
participants included in the registry were not rand-
omized to VNS + TAU or TAU. Rather, treatment was 
determined by a participant’s choice and availability of 
VNS Therapy.
The data from the VNS TRD registry revealed that 
the adjunctive VNS Therapy group had significantly 
higher 5-year cumulative response (67.6% vs 40.9%) 
and remission (43.3% vs 25.7%) rates compared to the 
TRD patients who received TAU alone (Aaronson et al. 
2017). Additionally, VNS + TAU led to a more durable 
response as the time-to-relapse from initial response 
for responders in the first year was 10.1  months ver-
sus 7.3  months for participants receiving TAU alone 
(Kumar et  al. 2019). Safety assessment in the registry 
also found a greater reduction in suicidality in partici-
pants receiving VNS + TAU compared to TAU alone 
(Aaronson et al. 2017).
Nierenberg and colleagues have previously described 
the outcomes of 25  patients with TRBD who were 
included in acute and long-term early studies of VNS 
Therapy for the treatment of depression (Nierenberg 
et  al. 2008). The authors reported that the antidepres-
sant efficacy outcomes for these TRBD patients were 
similar to the unipolar TRD patients.
Benefit of VNS Therapy in patients with bipolar 
disorder is also supported by a published case series 
that included 5 patients who demonstrated sustained 
improvement in depressive symptoms and a lack of 
manic episodes during the follow-up period; and 3 of 
these patients were followed for about 5 years (Oldani 
et al. 2015).
In this report—using the 5-year VNS TRD regis-
try discussed above—we examine the pre-treatment 
clinical characteristics and the clinical outcomes in 
a subgroup of TRD patients with TRBD comparing 
VNS + TAU versus TAU alone based on the following 
areas of interest:
Limitations: In this registry study, participants were not randomized to the study treatment group, VNS Therapy 
stimulation parameters were not controlled, and there was a high attrition rate over 5 years.
Trial registration ClinicalTrials.gov NCT00320372. Registered 3 May 2006, https ://clini caltr ials.gov/ct2/show/NCT00 
32037 2 (retrospectively registered)
Keywords: Bipolar disorder, Depression, Vagus Nerve Stimulation Therapy, VNS TRD registry, Response, Suicidality, 
Treatment‑resistant depression
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 I. Illness characteristics and previous treatments 
received prior to inclusion in the registry
 II. Cumulative depressive symptom response (defined 
by ≥ 50% reduction in Montgomery–Åsberg 
Depression Rating Scale [MADRS]) over the 5-year 
registry observation period
 III. Duration of response (defined a priori as mainte-
nance of ≥ 40% reduction from baseline MADRS)




Analysis of the 5-year VNS TRD registry data set 
described here included 156 participants with bipolar 
disorder (both bipolar I and II disorders): n = 97 received 
VNS + TAU and n = 59 received TAU. To be eligible to 
participate in the VNS TRD Registry, participants had 
to be over 18 years of age, experiencing an active major 
depressive episode of 2 years or longer in duration (either 
unipolar or bipolar), or had a history of at least 3 major 
depressive episodes, including the current depressive 
episode, and a history of inadequate response to 4 or 
more adequate antidepressant treatments (dosage per 
Physicians’ Desk Reference labeling for a minimum of 
4 weeks), which could include electroconvulsive therapy 
(ECT). Participants could not have a history of a psy-
chotic disorder or rapid-cycling bipolar disorder, or psy-
chotic features in the present major depressive episode. 
A more detailed list of study entry criteria can be found 
elsewhere (Aaronson et al. 2017; Olin et al. 2012). Clini-
calTrials.gov Identifier: NCT00320372.
Study treatment
Before enrollment into the VNS TRD Registry, partici-
pants could select the treatment group of their choice 
(ie,  TAU or VNS + TAU). The exception to this were 
those VNS + TAU subjects who entered the registry 
via rollover from a previous flexible dose-finding VNS 
trial (Aaronson et al. 2013). Some participants could be 
assigned to receive the alternate treatment by the site for 
various reasons, including availability of surgical implan-
tation at a site, number of allocated slots for implanta-
tion, or failure to qualify for insurance reimbursement or 
VNS Therapy implantation. Device implantation surgery 
and related medical care were covered either by a partici-
pant’s insurance policy or from personal funds.
Assessments
The assessment of the registry participants included in 
this analysis has been detailed elsewhere (Aaronson et al. 
2017). Participants in the VNS + TAU group underwent 
implantation during Visit 2 (baseline). Post-baseline fol-
low-up visits for all participants were conducted at 3, 6, 9, 
12, 18, 24, 30, 36, 42, 48, 54, and 60 months. The primary 
measure of depression for this registry was the MADRS 
(Carmody et al. 2006) which was administered by central 
blinded raters. Other psychiatric outcome measures were 
the Quick Inventory of Depressive Symptomatology–Self 
Report (QIDS-SR) (Trivedi et  al. 2004; Rush et  al. 2003) 
and the Clinical Global Impression (CGI) scale (Guy 1976).
Statistical analysis
The intent-to-treat (ITT) population included 195 
registry participants with bipolar disorder (n = 134 
VNS + TAU; n = 61 TAU) defined as those who com-
pleted their baseline visit, received their respective 
treatment, and completed at least one post-baseline 
assessment. To ensure consistent VNS Therapy dose 
and follow-up schedule, the analysis sample excluded 
individuals who were "crossed over" from VNS Therapy 
treatment in the previously reported flexible dose study 
(n = 37) since most of these participants had consistent 
follow-up data for only 1 year (Aaronson et al. 2013). In 
addition, we excluded participants who had a baseline 
MADRS score < 10 indicating that they were already 
remitted from their major depressive episode  (Zimmer-
man et al. 2004); this excluded n = 2 from the TAU group. 
The remaining 156 TRBD patients comprised of N = 97 
receiving VNS + TAU and N = 59 receiving TAU and 
were included in the analysis described here. Note that 
participants who were crossed over to another treatment 
group during the study were censored at the last visit 
before cross-over.
Time-to-initial response was defined as the time from 
baseline to the first visit when there was reduction in 
MADRS score of ≥ 50% compared to baseline. A prob-
ability of time-to-initial response was estimated using 
Kaplan–Meier (KM) method. KM probability estimates 
were calculated for the time-to-event with 95% confi-
dence intervals at 3, 6, 9, and 12 months. Time-to-event 
curves for the 2 treatment groups were compared using 
Log-rank test. A Cox proportional-hazard model was 
used to estimate the hazard ratio (and 95% confidence 
interval) of the instantaneous chance of a participant 
having an event in the VNS + TAU group compared to 
the TAU group at any given time during follow-up.
Given the different proportion of participants with 
bipolar I or II disorder between the VNS + TAU and TAU 
groups, a second Cox proportional-hazard model was 
used to evaluate the time-to-first response, adjusting for 
the effects of bipolar diagnosis and interaction between 
treatment and bipolar diagnosis.
Persistence of response was defined as an ongo-
ing reduction in MADRS score of ≥ 40% after an 
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antidepressant response was recorded (reduction of 
baseline MADRS of ≥ 50%). Persistence of response was 
calculated for all study participants who had an initial 
response in the first year of study treatment. Participants 
were categorized in subgroups by the visit when the ini-
tial response occurred. A KM analysis was performed to 
compare the retention of response in VNS + TAU and 
TAU alone in a time-to-event analysis framework.
Participants were considered severely suicidal if they 
had a score of ≥ 4 on MADRS Item  10. The percentage 
who were still severely suicidal was calculated for each 
post-baseline visit. Similarly, the percentage who were 
non-severely suicidal at baseline who became severely 
suicidal was calculated for each post-baseline visit. Aver-
age change in suicidality score for VNS + TAU and TAU 
on MADRS Item  10 is presented for each post-baseline 
visit.
If there were 1 or 2 consecutive missing data, then 
the data was imputed with the average of the 2 adjacent 
non-missing data. No imputation was done for 3 or more 
consecutive missing data points. After imputation, par-
ticipants were censored at the last visit with non-missing 
data for all the analysis. Thus, there were a total of 412 
visits with data for TAU group and 856  visits with data 
for VNS + TAU group in the censored data set. Imputa-
tion for a single missed data point in the censored data 
set was done for 32 visits (32/412 [7.8%]) of the available 
data for TAU group and for 59 visits (59/856 [6.9%]) of 
the available data for VNS + TAU group. Imputation for 
2  consecutive missing data points was done for 14  vis-
its (14/412 [3.4%]) of the available data for TAU group 
and for 28 visits (28/856 [3.3%]) of the available data for 
VNS + TAU group. Overall, there were 46 imputed data 
(46/412  [11.2%]) of available data in TAU group and 87 
imputed data (87/856 [10.2%]) of all available data) in 
VNS + TAU group.
This imputation method has desirable properties as 
detailed in Kumar et al. (2019). The data set has a regular 
response pattern (when defined as reduction of MADRS 
score of ≥ 50%), ie, the same response at the adjacent vis-
its around one missing data: 78.1% for TAU and 62.7% 
for VNS + TAU, and around 2 consecutive missing data 
items: 100% for TAU and 78.1% for VNS + TAU. Thus, 
occurrence of initial or second response could have been 
altered due to imputation only for 1.7% of the censored 
data for the TAU group and 3.3% of censored data in the 
VNS + TAU group. Similarly, the censored data set pro-
vided a regular response pattern (when defined as reduc-
tion of MADRS score of ≥ 40%) around 1 missing data: 
71.9% for TAU and 57.6% for VNS + TAU and around 2 
consecutive missing data: 100% for TAU and 78.6% for 
VNS + TAU. Thus, prolongation of the response mainte-
nance could have occurred in only 2.2% of the censored 
data in the TAU group and 3.6% of the censored data in 
the VNS + TAU group. Given this small percentage of 
data that could have an altered response pattern due to 
imputation, it was concluded that the imputation method 
would work well for this data set and that it could not 
have altered the result substantially in favor of any treat-
ment group.
Results
Sample demographics and illness characteristics
Table 1 summarizes demographic information and base-
line clinical characteristics for the analysis sample.
The age at onset of depressive symptoms (around 
19–20  years of age) and age at initial diagnosis of an 
episode of depression (around 8  years later) were simi-
lar between the groups. Overall, there were significantly 
higher proportion of participants with a bipolar  I diag-
nosis in the VNS + TAU group (n = 65 [67.0%] vs n = 28 
[47.5%]) and lower rate of those with a bipolar  II diag-
nosis (32 [33.0%] vs 31 [52.5%]) compared with the TAU 
group (Chi-squared test for homogeneity, p = 0.0158). 
The VNS + TAU group had experienced more episodes 
of lifetime depressive episodes than the TAU group, 
though this was not statistically significant. Moreover, 
the VNS + TAU group had a history of more psychiatric 
hospitalizations within the 5  years prior to entering the 
registry and had more lifetime suicide attempts. Further, 
the VNS + TAU subjects had greater depressive sympto-
mology as assessed by the MADRS, QIDS-SR, and CGI. 
Additionally, the VNS + TAU group scored significantly 
higher on the suicidality item of the MADRS Item 10.
Treatment histories are presented in Table  2. There 
was a very similar distribution of lifetime use of medica-
tions. The mean number of lifetime antidepressant treat-
ment courses was approximately 9, with a maximum of 
14 in both treatment groups. All study participants had 
received antidepressants in the past or present, and selec-
tive serotonin reuptake inhibitors (SSRIs) and serotonin 
and norepinephrine reuptake inhibitors (SNRIs) were the 
most frequently prescribed antidepressant medication 
classes. With regard to medications specifically recom-
mended in guidelines for bipolar depression (National 
Institute for Health and Care Excellence 2014), lamotrig-
ine was the drug most commonly prescribed, followed 
by quetiapine. About half of the VNS + TAU group had 
taken lithium or sodium valproate, slightly more than 
seen in the TAU group. Just over half of the VNS + TAU 
group had prior ECT treatment, with a smaller number 
in the TAU group (54% vs 39%). Most participants had 
received psychological therapies, with a lifetime fre-
quency of individual therapy being above 80% in both 
groups.
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Table 1 Demographic and baseline clinical characteristics
SD standard deviation
* P‑values are from two‑sided t‑test for comparing means assuming unequal variance or z‑test for comparing proportions





Mean age ± SD (years) 47.0 ± 10.2 47.8 ± 10.6 0.65
Female, n (%) 72 (74.2%) 47 (79.7%) 0.56
White, n (%) 93 (95.9%) 56 (94.9%) 1
Mean age ± SD at initial onset of depressive symptoms (years) 20.0 ± 11.5 18.9 ± 9.2 0.51
Mean age ± SD at initial diagnosis of depression (years) 26.9 ± 10.6 27.9 ± 11.6 0.59
Lifetime number of diagnosed depressive episode 20.7 ± 29.2 13.7 ± 23.2 0.10
Psychiatric hospitalizations within the 5 years prior to registry enrollment 3.6 ± 5.4 1.5 ± 2.1  < 0.001
Lifetime suicide attempts 2.7 ± 4.8 1.5 ± 2.9 0.05
DSM‑IV‑TR primary diagnosis, n (%)
 Bipolar I disorder, currently moderately severe major depressive episode 19 (19.6%) 18 (30.6%) 0.17
 Bipolar I disorder, currently severe major depressive episode 46 (47.4%) 10 (16.9%)  < 0.001
 Bipolar II disorder, currently depressed 32 (33.0%) 31 (52.5%) 0.025
Baseline scores, n (%)
 Montgomery–Åsberg Depression Rating Scale 33.7 ± 7.3 29.7 ± 5.9  < 0.001
 Clinical Global  Impression—Severity 5.2 ± 0.8 4.7 ± 0.7  < 0.001
 Quick Inventory of Depressive Symptomatology‑Self Report 18.4 ± 4.9 15.9 ± 5.2 0.004
 Suicidality‑based on MADRS Item 10 2.7 ± 1.4 2.0 ± 1.2 0.003
Table 2 Lifetime treatment histories
* A course of treatment was defined as at least a 4‑week continuous period in which a patient used one or more treatments for their depression. A new course of 
treatment started each time a drug was added or dropped. Courses of treatment were classified as electroconvulsive therapy, monotherapy, combination therapies, 
augmentation therapies, or other psychiatric treatments
VNS + TAU (N = 97) TAU (N = 59)
Number of treatment courses*
 Mean 9.2 9.0
 Maximum 14 14
 Minimum 3 4
Antidepressants, n (%) 97 (100%) 59 (100%)
 Bupropion 71 (73%) 38 (64%)
 Selective serotonin reuptake inhibitors (SSRIs) 88 (91%) 50 (85%)
 Serotonin and norepinephrine reuptake inhibitors (SNRIs) 78 (80%) 48 (81%)
 Other 68 (70%) 35 (59%)
Antipsychotics, anticonvulsants, and other medications, n (%)
 Lamotrigine 62 (64%) 44 (75%)
 Quetiapine 56 (58%) 35 (59%)
 Olanzapine 37 (38%) 24 (24%)
 Olanzapine + fluoxetine 5 (5%) 6 (10%)
 Lithium 53 (55%) 25 (42%)
 Sodium valproate 54 (56%) 20 (34%)
Electroconvulsive therapy, n (%) 53 (54%) 23 (39%)
Psychological therapies, n (%)
 Cognitive behavioral therapy (CBT) 44 (45%) 23 (39%)
 Individual therapy 83 (86%) 48 (81%)
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Cumulative response rates
Over the 5-year observation period, 61 of 97 (63%) in 
the VNS + TAU group had an initial response (defined 
as ≥ 50% reduction in MADRS from baseline) com-
pared to 23 of 59 (39%) of participants in the TAU 
group. The KM plot in Fig.  1 shows that time-to-ini-
tial response was significantly shorter for VNS + TAU 
than for TAU alone (p = 0.03 for log-rank test). The 
estimated cumulative probability for the time-to-ini-
tial response was higher for the VNS + TAU group 
as compared to the TAU group over most of the fol-
low-up period. Median time-to-initial response was 
13.7  month (Q1 = 5, Q3 = 37.7) for VNS + TAU group 
compared to 42.1  months (Q1 = 8.3, Q3 = not estima-
ble) for TAU group. Hazard ratio for time-to-initial 
response for VNS + TAU compared to TAU was 1.7 
(95% CI 1, 2.7) meaning a larger chance for a partici-
pant in the VNS + TAU group to get an initial response 
compared to a participant in the TAU group at any 
given time during the follow-up, though the hazard 
ratio was not statistically significant.
The Cox proportional-hazard model on time-to-first 
response adjusting for the effects of bipolar diagnosis 
and the correspondent interaction, confirmed the ben-
efit of VNS + TAU in reducing the time-to-first response 
(HR = 1.6; 95% CI 0.98, 2.7) and VNS + TAU showed 
trends of effectiveness in both sub-populations (HR = 2.1 
in bipolar I and HR = 1.3 in bipolar II, even if a signifi-
cant treatment effect of VNS + TAU vs TAU was seen 
just in the participants with bipolar  I (95% CI 1.0, 4.3) 
(Table 3). This may in part be driven by the smaller num-
ber of patients with bipolar II vs bipolar I disorder (n = 59 
vs n = 97) and the low rate of responses in the bipolar II 
subgroup (n = 17 vs n = 14 for the VNS + TAU and TAU 
groups, respectively). Due to the low rate, it was also 
not possible to estimate the 95% confidence intervals in 
KM analysis for the median time-to-first response in the 
bipolar II patients (Table 4).
Duration of response
Maintenance of response was defined a priori as main-
tenance of ≥ 40% reduction from baseline MADRS 
Participants with available response data by visit (month, m)
Treatment
group 0 m 6 m 12 m 18 m 24 m 30 m 36 m 42 m 48 m 54 m 60 m
VNS+TAU 97 65 42 31 23 19 16 12 11 9 7
TAU 59 43 27 16 14 13 12 11 8 6 3
Fig. 1 Kaplan–Meier plot for time‑to‑initial response based on MADRS score
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and assessed in those who showed a response in the 
first year of follow-up. In the VNS + TAU group, 46 of 
the 61 responders (75.4%) responded in the first year; 
and in the TAU group, 19 of the 23 responders (82.6%) 
responded in the first year. Numbers are small and 
hence comparisons between the 2 groups may not be 
robust.
A KM analysis of the data estimated that the 
median time-to-relapse from initial response in the 
first year was 15.2  months (Q1 = 6.7, Q3 = 25.4) for 
the VNS + TAU group compared with 7.6  months 
(Q1 = 3.4, Q3 = 14.7) for the TAU group. The hazard 
ratio for relapse after the initial response was 0.7 (95% 
CI 0.3, 1.4) in favor of VNS, though this was not statis-
tically significant. In terms of actual data, it was pos-
sible to examine maintenance of response 6  months 
after initial response in participants who demon-
strated an initial response at the 3-, 6-, or 12-month 
study visits. Of these, 30/39 (76.9%) in the VNS + TAU 
group were maintaining a response 6  months later, 
compared with 10/18 (55.6%) in the TAU group. There 
was limited data to examine maintenance of response 
12  months after initial response since this was only 
available for those who showed an initial response at 
the 6- or 12-month visits. However, again, the propor-
tion maintaining a response was numerically higher 
in the VNS + TAU compared with TAU group (6/13 
[46.1%] vs 3/11 [27.3%], respectively).
Suicidality
A total of 33 (33/97; 34%) in the VNS + TAU group and 
8  (8/59; 14%) in the TAU group were severely suicidal 
at baseline based on MADRS (a score ≥ 4 on MADRS 
Item 10 corresponding to the responses “probably better 
off dead” and “active preparations for suicide”). Notably, 
the mean reduction in suicidality score across the study 
visits was significantly greater in the VNS + TAU than in 
the TAU group (P < 0.001 as per F-test) (Fig. 2).
In each treatment group, the percentage who became 
severely suicidal post-baseline was less than 15% (Table 5) 
and the difference between the treatment groups was not 
statistically significant.
Discussion
Given the frequency of TRBD and its impact on patients 
with bipolar disorder, it is important to consider all pos-
sible treatment options. This post-hoc analysis suggests 
that in a non-randomized study following the outcomes 
of patients with TRBD for up to 5 years, the addition of 
VNS Therapy to TAU had significantly greater cumulative 
response rates, faster onset of antidepressant response, 
and the responses were longer in duration than in par-
ticipants receiving TAU alone. Critically, VNS + TAU 
was also associated with a significantly greater reduction 
in suicidal ideation compared with TAU alone, despite 
the VNS + TAU group being more severely depressed 
at baseline and with high ratings of suicidality. These 
findings are consistent with the observations made in a 
much larger group of patients with unipolar or bipolar 
depression (Aaronson et al. 2017). They are also consist-
ent with a previous post-hoc analysis of 25 patients with 
TRBD who made up 11% of a larger TRD population 
who received VNS Therapy alongside TAU in a sham-
controlled acute study with long-term open-label follow-
up (Nierenberg et al. 2008). The only other study of the 
safety and efficacy of VNS Therapy in bipolar disorder 
is a 1-year pilot study of VNS Therapy in 9 patients with 
rapid cycling bipolar disorder that did not have a com-
parator group (Marangell et al. 2008).
These findings suggest that VNS Therapy may be effec-
tive in patients with very significant difficult to treat 
Table 3 Cox proportional-hazards model examining effect 
of bipolar diagnosis on the time-to-first response





VNS + TAU vs TAU 1.6 0.98 2.7 0.06
Bipolar II vs 
bipolar I
0.96 0.6 1.6 0.9
VNS vs TAU in 
bipolar I
2.1 1.0 4.3 0.04
VNS vs TAU in 
bipolar II
1.3 0.6 2.6 0.5
Table 4 Kaplan–Meier estimates for time-to-first response, months
CI confidence interval, NE not estimable
First quartile (95% CI) Median (95% CI) Third quartile (95% CI)
Bipolar 1
 VNS + TAU 5.8 (4.1, 7.7) 13 (7.7, 23.2) 36.6 (23.2, NE)
 TAU 13.1 (4, 37) 37 (13.1, NE) NE (37, NE)
Bipolar 2
 VNS + TAU 4.7 (3.7, 10.4) 19.5 (9.2, NE) NE (24.8, NE)
 TAU 7.9 (4.3, 13.2) 14.3 (8.3, NE) NE (48.8, NE)
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depression in the context of bipolar disorder. Those 
treated with VNS Therapy had an average of 20.7 life-
time episodes of depression, 3.6 psychiatric hospitali-
zations in the previous 5  years, and 2.7  lifetime suicide 
attempts. They had received an average of 9 media-
tion treatment courses over their lifetime and all had 
received an antidepressant, despite the lack of evidence 
that these are efficacious in patients with bipolar disorder 
(Sidor and Macqueen 2011; Young et al. 2010). The vast 
majority had also received psychotherapy, and about half 
(54%) had been treated with ECT. Importantly, despite 
the VNS + TAU participants having considerably more 
severe depressive histories (statistically significantly more 
severe depressive symptomology and greater suicidal 
ideation at baseline prior to treatment), the VNS + TAU 
group demonstrated superior antidepressant outcomes.
The magnitude of the effect on cumulative response 
rates with VNS + TAU versus TAU was slightly larger 
than that seen in patients with unipolar depression in 
the original analysis of this data set (Aaronson et  al. 
2017). However, the assessment of the impact of VNS 
Therapy on durability of response in this current analy-
sis is not as great as that seen in the unipolar patients 
studied as part of this registry (Kumar et  al. 2019). 
This is perhaps not surprising given that bipolar dis-
order is more recurrent than unipolar disorder (Angst 
et  al. 2003). While there was no significant difference 
in durability of response between the VNS + TAU and 
TAU groups in this analysis, numerically the partici-
pants receiving VNS + TAU did better. The lack of sig-
nificant findings with regards to durability of response 
may have in part arisen due to the small numbers 
of patients included in the analysis, particularly at 
later visit time points, and the relative infrequency of 
assessment of mood symptoms. Given the importance 
of prophylaxis in a recurrent disorder such as bipolar 
disorder, further research investigating the prophylac-
tic efficacy of VNS Therapy is indicated, including in 
Patients with available suicidality data on MADRS item 10 by visit
trt 3m 6m 9m 12m 18m 24m 30m 36m 42m 48m 54m 60m
VNS + TAU 89 77 66 67 61 62 52 53 48 44 32 40
TAU 52 46 36 34 25 21 16 18 19 20 13 16















































Fig. 2 Mean change in suicidality score from baseline based on MADRS Item 10
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patients with rapid cycling, utilizing frequent assess-
ments of symptoms.
Previous analyses in a mixed, but predominantly uni-
polar TRD population, have suggested a reduction in 
rates of suicide and all-cause mortality associated with 
VNS treatment (Aaronson et  al. 2017; Feldman et  al. 
2013). The significant reductions in suicidality seen in 
this post-hoc analysis of patients with TRBD treated 
with VNS Therapy suggests that such findings might 
be expected in a larger population of individuals with 
TRBD, though further research is required. Similarly, it 
is important to further explore whether the cost effec-
tiveness of VNS Therapy, observed in mixed TRD pop-
ulations (predominantly unipolar depression), will also 
be observed in TRBD patients (Feldman et al. 2013).
VNS Therapy is generally well tolerated as revealed in 
a meta-analysis of over 1000 patients with either uni-
polar or bipolar depression (Berry et  al. 2013). Data 
regarding the impact of adverse effects of medication 
was not available in the specific sub-sample of bipo-
lar patients reported here. However, in the complete 
sample of unipolar and bipolar patients in the regis-
try study (Aaronson et  al. 2017), medication adverse 
effects were assessed using the frequency, intensity, 
and burden of side effects rating (FIBSER) scale (Wis-
niewski et al. 2006). Based on this scale, the patients in 
the VNS + TAU group reported higher scores for fre-
quency, severity, and burden of side effects at baseline, 
but at the 12 and 24 months timepoints, there were no 
significant differences between the groups (data avail-
able on request).
There was a significant difference in the propor-
tion of bipolar I participants in the two groups (67% 
in TAU + VNS vs 47% in TAU) and it is possible that 
this, in part, impacted the results. A significant effect 
of VNS + TAU over TAU was seen for time-to-first 
response in bipolar I participants (HR = 2.1; 95% CI 1, 
4.3). This was not evident in those with bipolar II disor-
der, though the event rate was such that it is not possible 
to draw meaningful conclusions regarding a bipolar I vs 
bipolar II difference in the effectiveness of VNS Therapy 
added to TAU. In addition, this registry study unfortu-
nately did not collect formal ratings of manic symptoms, 
so it is not possible to infer the effects of VNS Therapy on 
elevated mood. A previous 12-month follow-up study of 
VNS Therapy that included 20 patients with bipolar dis-
order assessed manic symptoms (Rush et al. 2005). Two 
of the participants developed brief mild manic episodes 
that lasted 1 to 2 weeks, and there were two short peri-
ods of sub-syndromal hypomanic symptoms (about 1 to 
3 days), during the first 3 months of treatment with VNS 
Therapy. One participant (with a baseline diagnosis of 
unipolar disorder) developed a manic episode during the 
subsequent 9  months of treatment with VNS Therapy. 
Additional data are required to address whether there are 
potential differential effects between bipolar I vs II and 
the effect of VNS Therapy on hypomanic/manic symp-
toms, and such data will hopefully become available fol-
lowing completion of the current ongoing RECOVER 
randomized trial in the USA and the RESTORE-LIFE 
registry in Europe.
The study had several additional limitations. Partici-
pants were not randomized to the treatment groups, and 
when VNS Therapy was an available treatment option, 
there appeared to be a tendency for the treatment to be 
utilized in patients with bipolar disorder who had a sig-
nificant degree of pharmacological non-response (or 
intolerance) and who had a higher rate of ECT treat-
ment history (54%). This rate of ECT usage is similar to 
that seen in the unipolar patients included in the registry 
(61%) who received VNS. In addition, there was no sham 
VNS for the “TAU” group. Therefore, it is not possible to 
conclude with high certainty that all the effects observed 
are exclusively related to treatment with adjunctive 
VNS Therapy. The higher baseline MADRS score in the 
VNS + TAU compared with TAU group might also mean 
that regression to the mean may have played a larger 
role in the VNS + TAU group. In this effectiveness trial, 
medications and all other treatments, such as TMS and 
ECT, could change during treatment for either treatment 
group. Furthermore, study participants and clinicians 
were knowledgeable about the care being given. How-
ever, the off-site central raters collecting the MADRS 
data were blind to both treatment group and the overall 
Table 5 Change in  suicidal rating from  non-severe 
to severe based on MADRS Item 10
The numerator denotes the number of participants who had a non‑severe 
suicidal rating at baseline (score < 4) and developed a severe suicidal rating 
(score ≥ 4) at a post‑baseline visit based on MADRS Item 10. The denominator 
denotes the number of participants who had a non‑severe suicidal rating at 
baseline and attended a post‑baseline visit
Visit months VNS + TAU TAU 
3 3/57 (5.3%) 3/44 (6.8%)
6 2/49 (4.1%) 4/40 (10%)
9 1/43 (2.3%) 2/32 (6.3%)
12 6/44 (13.6%) 2/28 (7.1%)
18 1/39 (2.6%) 1/22 (4.5%)
24 0/36 (0%) 0/19 (0%)
30 1/29 (3.4%) 0/14 (0%)
36 1/30 (3.3%) 0/16 (0%)
42 1/28 (3.6%) 1/15 (6.7%)
48 2/27 (7.4%) 1/18 (5.6%)
54 1/18 (5.6%) 1/10 (10%)
60 2/23 (8.7%) 0/14 (0%)
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clinical status of the study participants. The population 
examined limits generalizability, though it is of course 
reasonably representative of participants suffering from 
a significant degree of difficult to treat depression in the 
context of bipolar disorder. Suicidality was not assessed 
using a specific suicidality scale, but rather a single item 
in the MADRS. Finally, in this 5-year longitudinal study, 
the participant attrition over time limits our ability to 
address with significant sample sizes some of the ques-
tions that are posed.
Conclusions
VNS Therapy as an adjunctive treatment to TAU was 
more effective than TAU alone in reducing depressive 
symptomatology, and led to a greater reduction in sui-
cidal ideation, and, on average, a more rapid antide-
pressant response. Further, the antidepressant effects 
observed in the VNS + TAU group vis-à-vis TAU were 
likely more durable. Together, these findings support 
previously observed findings that adjunctive VNS is 
an efficacious antidepressant treatment in very severe, 
treatment-resistant bipolar depression.
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